You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed / refractory AML

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial (Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Gilteritinib 40 MG Oral Tablet
  • +4 more
  • Lexington, Kentucky
    University of Kentucky
Oct 27, 2022

Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Miami, Florida
    University of Miami
Dec 22, 2022

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, MDS Trial (biological, drug, procedure)

Withdrawn
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Cytokine-induced memory-like NK cells
  • +4 more
  • (no location specified)
Feb 23, 2022

AML, Adult Trial in Tianjin (QN-023a, Cyclophosphamid, Fludarabine)

Recruiting
  • AML, Adult
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 3, 2022

Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) Trial in United States (voruciclib

Recruiting
  • Follicular Lymphoma (FL)
  • +6 more
  • voruciclib monotherapy
  • voruciclib and venetoclax
  • Duarte, California
  • +10 more
Aug 10, 2022

Xospata in Relapsed or Refractory Acute Myeloid Leukemia With

Recruiting
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
  • Gilteritinib Exposure
  • Goyang-si, Gyeonggi-do, Korea, Republic of
  • +4 more
Aug 18, 2022

AML, Childhood Trial in United States (Nivolumab, 5-azacytidine)

Active, not recruiting
  • AML, Childhood
  • Los Angeles, California
  • +11 more
Oct 10, 2022

Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia (AML)
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Feb 6, 2022

Leukemia, Myeloid, Acute Trial (GSK3745417)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Jun 15, 2022

Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

Recruiting
  • Acute Myeloid Leukemia
  • CLL1 and CD38 dual-target CAR-T injection
  • Kunming, Yunnan, China
    920th Hospital of Joint LogisticsSupport Force of People's Liber
Oct 26, 2023

AML Trial in Hangzhou (ADGRE2 CAR-T)

Not yet recruiting
  • AML
  • ADGRE2 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 17, 2022

Relapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia Trial in Kansas City (Daunorubicin)

Recruiting
  • Relapsed Pediatric ALL
  • +3 more
  • Kansas City, Missouri
    Children's Mercy Hospital
Jul 1, 2022

Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

Not yet recruiting
  • Leukemia, Acute Myeloid (AML)
  • (no location specified)
Oct 16, 2022

AML Trial in Hangzhou (CLL1 CAR-T)

Not yet recruiting
  • AML
  • CLL1 CAR-T
  • Hangzhou, China
    The First Affiliated Hospital, Zhejiang University
Jul 17, 2022

Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Frankfurt am Main, Hannover, Hamburg (Selinexor, Idarubicin, Cytarabine)

Completed
Has Results
  • Acute Myeloid Leukemia (Relapsed/Refractory)
  • Frankfurt am Main, Hessen, Germany
  • +2 more
Aug 1, 2021

Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
Feb 22, 2022

AML Trial in Hangzhou (CLL1+CD33 CAR-T)

Not yet recruiting
  • AML
  • CLL1+CD33 CAR-T
  • Hangzhou, China
    Mingming Zhang Zhang
Jul 19, 2022

AML Trial in Hangzhou (CD33 CAR-T)

Not yet recruiting
  • AML
  • CD33 CAR-T
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Jul 21, 2022

AML Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • AML
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

NHL, Adult, AML, Adult Recurrent Trial in Zhengzhou, Tianjin (ETH-155008)

Recruiting
  • NHL, Adult
  • AML, Adult Recurrent
  • Zhengzhou, Henan, China
  • +1 more
Feb 24, 2023

Acute Myeloid Leukemia, in Relapse Trial in Baltimore, Chapel Hill (pembrolizumab,)

Active, not recruiting
Has Results
  • Acute Myeloid Leukemia, in Relapse
  • Baltimore, Maryland
  • +1 more
Aug 10, 2022

Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult Trial in

Terminated
  • Acute Myelogenous Leukemia in Relapse
  • +4 more
  • Tucson, Arizona
  • +12 more
Aug 18, 2022

Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
  • Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
  • Gemtuzumab Ozogamicin
  • Dresden, Germany
  • +1 more
Dec 20, 2022

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (BP1002; Liposomal Bcl-2 Antisense

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
  • Decitabine (in combination with BP1002)
  • (no location specified)
Mar 8, 2022

AML Trial in Hangzhou (MAX-40279-01)

Recruiting
  • AML
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Jan 18, 2022